Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Cancer development and chemo-resistance are often due to impaired functioning of the p53 tumor suppressor through genetic mutation or sequestration by other proteins. In glioblastoma multiforme (GBM), p53 availability is frequently reduced because it binds to the Murine Double Minute-2 (MDM2) oncoprotein, which accumulates at high concentrations in tumor cells. The use of MDM2 inhibitors that interfere with the binding of p53 and MDM2 has become a valid approach to inhibit cell growth in a number of cancers; however little is known about the efficacy of these inhibitors in GBM. We report that a new small-molecule inhibitor of MDM2 with a spirooxoindolepyrrolidine core structure, named ISA27, effectively reactivated p53 function and inhibited human GBM cell growth in vitro by inducing cell cycle arrest and apoptosis. In immunoincompetent BALB/c nude mice bearing a human GBM xenograft, the administration of ISA27 in vivo activated p53, inhibited cell proliferation and induced apoptosis in tumor tissue. Significantly, ISA27 was non-toxic in an in vitro normal human cell model and an in vivo mouse model. ISA27 administration in combination with temozolomide (TMZ) produced a synergistic inhibitory effect on GBM cell viability in vitro, suggesting the possibility of lowering the dose of TMZ used in the treatment of GBM. In conclusion, our data show that ISA27 releases the powerful antitumor capacities of p53 in GBM cells. The use of this MDM2 inhibitor could become a novel therapy for the treatment of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Costa et al. demonstrated that TMZ synergized with the MDM2 PPI inhibitor ISA27 to kill U87-MG cells in vitro”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An increase in p53 expression (but not p21 nor MDM2) was observed in tumors at relapse, potentially associated with the emergence of TP53 mutant tumor cell subpopulations, as it was reported previously (reviewed in [36]).”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Although it has been shown that nutlin3a and other MDM2 PPI inhibitors have single-agent activity in inhibiting the growth of a variety of tumor types including GBM”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
In the citing paper
“and administration of ISA27 alone inhibited growth of GBM flank xenografts.13”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“The cytosolic protein content was determined as previously described [36], and the cytochrome C content was determined using the Platinum Human Cytochrome C ELISA.”
MethodIsolation of mononuclear cells and granulocytes from human blood.
Bøyum, A. (1968) · Scandinavian Journal of Clinical and Laboratory Investigation · Cited by 9,585
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“The senescence marker, Senescence-associated beta-galactosidase (SA-b-Gal), was detected as previously described [35], and the cells were then washed in PBS (16) and photographed at 1006 magnification.”
MethodIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14,24] were reported to be effective at inhibiting GBM cell growth in vitro [14,24,25], suggesting the validity of this experimental approach for the treatment of GBM.”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414 · cited 1×
“A graphical assessment of synergy with regard to growth inhibition was performed using isobolographic analysis [39,40].”
MethodGenetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · cited 1×
“Interestingly, MDM2 inhibitors have been reported to induce cancer cell apoptosis even without the concomitant application of genotoxic stimuli [17,18,20].”
BackgroundFunctions of the MDM2 oncoprotein
Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050273 · Cited by 577 · cited 1×
“The cumulative evidence of aberrantly increased activity of the primary p53 inhibitor MDM2 in GBM [11,12] prompted us to examine the effects of targeted inhibition of the MDM2-p53 interaction by the spiro-oxindole analogue ISA27, a recently described smallmolecule inhibitor of MDM2 [26].”
BackgroundMDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · cited 1×
“It has been demonstrated that Nutlin-3 is not toxic to peripheral blood mononuclear cells, bone marrow-derived haematopoietic progenitors and bone marrow stromal epithelial cells [48–50].”
BackgroundGenetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355 · cited 3×
“inducing collateral DNA damage offers a tantalising solution to the shortcomings of current therapeutic regimens and appears to be a reasonable approach for GBM therapy in view of the infrequent occurrence of p53 gene mutations [9,10].”
BackgroundPTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy
Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351 · cited 1×
“In these cell lines, the primary mechanism of p53 inactivation is the high nuclear MDM2 levels caused by a lack of PTEN, a tumor suppressor protein that normally counteracts MDM2 translocation into the nucleus [46].”
BackgroundAutomated Network Analysis Identifies Core Pathways in Glioblastoma
Cerami, E., Demir, E., Schultz, N., Taylor, B. S., & Sander, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008918 · Cited by 333 · cited 3×
“inducing collateral DNA damage offers a tantalising solution to the shortcomings of current therapeutic regimens and appears to be a reasonable approach for GBM therapy in view of the infrequent occurrence of p53 gene mutations [9,10].”
BackgroundThe interaction index: a measure of drug synergism
Tallarida, R. J. (2002) · Pain · doi:10.1016/s0304-3959(02)00041-6 · Cited by 290
Adult glioma incidence trends in the United States, 1977–2000
Hess, K. R., Broglio, K. R., & Bondy, M. L. (2004) · Cancer · doi:10.1002/cncr.20621 · Cited by 270
Statistical analysis of drug combinations for synergism
Tallarida, R. J. (1992) · Pain · doi:10.1016/0304-3959(92)90193-f · Cited by 236 · cited 1×
“A graphical assessment of synergy with regard to growth inhibition was performed using isobolographic analysis [39,40].”
MethodVandesompele, J., De Paepe, A., & Speleman, F. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5564 · Cited by 231 · cited 1×
“The relative quantification of p53 mRNA was performed by real-time reverse transcription polymerase chain reaction (realtime RT-PCR) as previously described [31] in MDM2 inhibitortreated and untreated GBM cells.”
MethodLiu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 228 · cited 1×
“Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14,24] were reported to be effective at inhibiting GBM cell growth in vitro [14,24,25], suggesting the validity of this experimental approach for the treatment of GBM.”
BackgroundCaMK4 Gene Deletion Induces Hypertension
Santulli, G., Cipolletta, E., Sorriento, D., Del Giudice, C., Anastasio, A., Monaco, S., Maione, A. S., Condorelli, G., Puca, A., Trimarco, B., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001081 · Cited by 213 · cited 1×
“For the toxicity assay, Masson trichrome staining was performed on paraffin sections from the liver, kidney and lung of mice treated with intra-peritoneal injections of ISA27 and control mice as previously described [38].”
MethodSelf-citationNongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1489 · Cited by 180 · cited 1×
“It has been demonstrated that Nutlin-3 is not toxic to peripheral blood mononuclear cells, bone marrow-derived haematopoietic progenitors and bone marrow stromal epithelial cells [48–50].”
BackgroundSecchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4465 · Cited by 158 · cited 1×
“It has been demonstrated that Nutlin-3 is not toxic to peripheral blood mononuclear cells, bone marrow-derived haematopoietic progenitors and bone marrow stromal epithelial cells [48–50].”
BackgroundLiu, J., Ma, Q., Zhang, M., Wang, X., Zhang, D., Li, W., Wang, F., & Wu, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.001 · Cited by 129 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundVillalonga-Planells, R., Coll-Mulet, L., Martínez-Soler, F., Castaño, E., Acebes, J.-J., Giménez-Bonafé, P., Gil, J., & Tortosa, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018588 · Cited by 129 · cited 3×
“This finding is consistent with literature that has reported U87MG cell apoptosis after Nutlin-3 treatment for 96 h [25].”
BackgroundResultp53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
Chappell, W. H., Lehmann, B. D., Terrian, D. M., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22852 · Cited by 112
Kondo, S., Barnett, G. H., Hara, H., Morimura, T., & Takeuchi, J. (1995) · PubMed · Cited by 112
Chelli, B., Lena, A., Vanacore, R., Pozzo, E. D., Costa, B., Rossi, L., Salvetti, A., Scatena, F., Ceruti, S., Abbracchio, M. P., et al. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.008 · Cited by 97 · cited 5×
“The effects of MDM2 inhibitor treatment on U87MG cell survival/growth were determined by MTS conversion and Trypan blue exclusion assays [32,33].”
MethodInfluentialSelf-citationShangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Small-Molecule Inhibitors of the p53-MDM2 Interaction
Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 87 · cited 1×
“Interestingly, MDM2 inhibitors have been reported to induce cancer cell apoptosis even without the concomitant application of genotoxic stimuli [17,18,20].”
BackgroundResponse Surface Analysis of Synergism Between Morphine and Clonidine
Tallarida, R. J., Stone, D. J., McCary, J. D., & Raffa, R. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38100-5 · Cited by 85 · cited 1×
“The theoretical IC50,add value was then compared with the experimental IC50,mix to determine whether there was a statistically significant difference [41].”
MethodTemozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme
Nagasawa, D. T., Chow, F. E., Yew, A. Y., Kim, W. B., Cremer, N., & Yang, I. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.01.007 · Cited by 84 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundGomez-Monterrey, I., Bertamino, A., Porta, A., Carotenuto, A., Musella, S., Aquino, C., Granata, I., Sala, M., Brancaccio, D., Picone, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100838z · Cited by 82
Self-citationAzmi, A. S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P. A., Sarkar, F. H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.015 · Cited by 67 · cited 1×
“To the best of our knowledge, no data are available about molecular p21 involvement in MDM2 inhibitor effects except in p21-downregulated pancreatic cancer cells, in which the block of the apoptotic potential by the MDM2 inhibitor MI-319 has been demonstrated [19].”
BackgroundTabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64 · cited 2×
“The implication of this result can be illustrated from the recent Phase I study that showed the clinical efficacy of the MDM2 inhibitor, JNJ-26854165, in patients with advanced solid tumors, but at elevated doses, some toxic effects were reported [47].”
BackgroundResultWang, C.-C., Liao, Y.-P., Mischel, P. S., Iwamoto, K. S., Cacalano, N. A., & McBride, W. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0185 · Cited by 60
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58 · cited 2×
“Indeed, it has been demonstrated that a number of small-molecule MDM2 inhibitors can disrupt the MDM2-p53 interaction, release p53 from negative control and activate the p53 pathway, leading to cell cycle arrest and apoptosis in a number of solid cancers and haematological malignancies [14–17].”
BackgroundAnalysis of glioma cell lines for amplification and overexpression of MDM2
He, J., Reifenberger, G., Liu, L., Collins, V. P., & James, C. D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110205 · Cited by 56 · cited 1×
“The cumulative evidence of aberrantly increased activity of the primary p53 inhibitor MDM2 in GBM [11,12] prompted us to examine the effects of targeted inhibition of the MDM2-p53 interaction by the spiro-oxindole analogue ISA27, a recently described smallmolecule inhibitor of MDM2 [26].”
BackgroundVaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55 · cited 1×
“Analysis of p53 Protein Stabilisation Following GBM cell treatment with MDM2 inhibitor, stabilisation of the p53 protein was evaluated as previously described [28–30].”
Methodp53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors
Henze, J., Mühlenberg, T., Simon, S., Grabellus, F., Rubin, B. P., Taeger, G., Schüler, M., Treckmann, J. W., Dêbiec‐Rychter, M., Taguchi, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037776 · Cited by 54 · cited 2×
“Indeed, it has been demonstrated that a number of small-molecule MDM2 inhibitors can disrupt the MDM2-p53 interaction, release p53 from negative control and activate the p53 pathway, leading to cell cycle arrest and apoptosis in a number of solid cancers and haematological malignancies [14–17].”
BackgroundChemotherapy and novel therapeutic approaches in malignant gliomas
Desjardins, A. (2005) · Frontiers in bioscience · doi:10.2741/1727 · Cited by 52 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundRuan, S., Okcu, M. F., Pong, R. C., Andreeff, M., Levin, V. A., Hsieh, J. T., & Zhang, W. (1999) · PubMed · Cited by 51
Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells
Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.015 · Cited by 48 · cited 1×
“Interestingly, MDM2 inhibitors have been reported to induce cancer cell apoptosis even without the concomitant application of genotoxic stimuli [17,18,20].”
BackgroundSosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 42 · cited 1×
“Analysis of p53 Protein Stabilisation Following GBM cell treatment with MDM2 inhibitor, stabilisation of the p53 protein was evaluated as previously described [28–30].”
MethodA new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity
Sorriento, D., Campanile, A., Santulli, G., Leggiero, E., Pastore, L., Trimarco, B., & Iaccarino, G. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-97 · Cited by 39 · cited 1×
“For tumor formation, a suspension containing 2610 U87MG cells in 200 ml of culture medium were injected subcutaneously in the dorsal side of nude mice as previously described [37].”
MethodSelf-citationLee, S., Kim, Y. C., Song, S. B., & Kim, Y. S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.077 · Cited by 32 · cited 1×
“Analysis of p53 Protein Stabilisation Following GBM cell treatment with MDM2 inhibitor, stabilisation of the p53 protein was evaluated as previously described [28–30].”
MethodChelli, B., Rossi, L., Pozzo, E. D., Costa, B., Spinetti, F., Rechichi, M., Salvetti, A., Lena, A., Simorini, F., Vanacore, R., et al. (2005) · ChemBioChem · doi:10.1002/cbic.200400350 · Cited by 26
Self-citationAdvances in Chemotherapy for Brain Tumors
Conrad, C. A., Milosavljevic, V. P., & Yung, W. K. A. (1995) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30018-5 · Cited by 25 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundHalatsch, M., Schmidt, U. I., Unterberg, A. W., & Vougioukas, V. I. (2006) · PubMed · Cited by 23
Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy
Li, C. V., Shen, J., Wei, X., Xie, C., & Lu, W. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2011.645162 · Cited by 20 · cited 1×
“Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14,24] were reported to be effective at inhibiting GBM cell growth in vitro [14,24,25], suggesting the validity of this experimental approach for the treatment of GBM.”
BackgroundMDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells
Ghassemifar, S., & Mendrysa, S. M. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.022 · Cited by 19 · cited 1×
“Moreover, many laboratories have shown that MDM2 inhibitors can synergise with conventional chemotherapeutic agents, resulting in enhanced efficacy [18–22].”
BackgroundOverexpression of MDM2, p53, and NCAM proteins in human radiation-induced skin ulcers.
Zhao, P., Wang, D., Gao, Y., Yang, Z., & Li, X. (1998) · PubMed · Cited by 3
Research works printed but not linked: 1
- Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles of oncology. Philadelphia: Lippincott-Raven. 2100–2161.
Cited by
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
“As an illustration, novel MDM2 inhibitors have been reported to inhibit the growth of TP53-wild-type glioblastoma PDCLs, regardless of the tumor MDM2 amplification status [117, 118].”
BackgroundTargeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
“Apart from DNA repair systems, it has been demonstrated that other factors, including epidermal growth factor receptor (EGFR) [31], phosphatase and tensin homolog (PTEN) [32], galectin-1 [33], murine double minute 2 (Mdm2) [34], p53 [35], PI3K/AKT/mTOR pathway [36], and sphingosine-1-phosphate/ sphingosine kinases [37…”
BackgroundMolecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
“MDM2 and MDM4 amplifications result in p53 inactivation and MDM2 inhibition has recently emerged as a strategy to restore p53 function [139,140].”
BackgroundGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 157
“Most GBMs harbor recurrent molecular alterations disrupting core pathways involved in regulation of growth (EGFR [9,10], PDGFRA [11], FGFR [12,13], mitogen-activated protein kinase (MAPK) [14,15] and phosphoinositide 3-kinase (PI3K) [16,17] signaling pathways), cell cycle [18–21], autophagy [22], DNA repair, and apopt…”
Background
Metadata
- Authors
- Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., Sorriento, D., Del Giudice, C., Iaccarino, G., Novellino, E., & Martini, C.
- Affiliations
- University of Pisa (IT)
- Ospedale Cisanello (IT)
- University of Salerno (IT)
- University of Naples Federico II (IT)
- Corresponding author
- Costa, Barbara
- Martini, Claudia
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-19
- Volume
- 8
- Issue
- 8
- Pages
- e72281
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3747081
- OpenAlex
- W1999920903
- Cited by
- 79
- References
- 53
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 9 · 2018: 12 · 2017: 10 · 2016: 11 · 2015: 6 · 2014: 4
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- glioblastoma, MDM2 inhibitors, p53 reactivation, temozolomide combination therapy, apoptosis, cell cycle arrest, tumor xenografts, small molecule inhibitors, chemoresistance
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Female, Glioblastoma, Humans, Indoles, Mice, Inbred BALB C, Mice, Nude, Protein Binding, Spiro Compounds, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Tumor Burden, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.